Effect of Baseline Hemoglobin Level on Prognosis in Nasopharyngeal Cancer Patients Receiving Chemoradiotherapy
Main Article Content
Abstract
Objective: To explore retrospectively how pretreatment hemoglobin levels affected the prognosis of patients with nasopharyngeal cancer receiving chemoradiotherapy.
Methods: Clinical data of 97 nasopharyngeal cancer patients who received definitive chemoradiotherapy between 2000 and 2022 were analyzed. We accepted the cut-off value of hemoglobin as 11.0g/dL.
Results: In general, 13 (13%) of patients were Hb≤11g/dL, while 84 (86%) was Hb>11g/dL. Median survival times were 76 (95%CI 19-132) months and 205 (95%CI 157-252) months for Hb≤11g/dL and Hb>11g/dL patients, respectively. 1, 2, 3 and 5 year survival rates were 67.7%, 67.7%, 67.7% and 58% for Hb≤11g/dL and 90.3%, 83.6.2%, 75.2% and 66.1% for Hb>11g/dL patients, respectively, and this difference show no statistical significance (p=0.254). When we evaluated patients according to WHO criteria for anemia (hemoglobin <12g/dL (female) or <13g/dL (male)), the median survival time was 220 (95%CI 190-255) months for non-anemic patients whereas it was 76 (95%CI 0-157) months for anemic patients. 1, 2, 3 and 5 year survival rates were 92.5%, 87.6%, 78.8% and 68.9% for non-anemic and 75%, 67.5%, 63.7% and 55.8% for anemic patients, respectively. There was statistically significant difference between the two groups (p=0.013).
Conclusion: In our study, although Hb<11g/dl before chemoradiotherapy did not show a statistically significant difference in nasopharyngeal cancer patients, the median overall survival of 76 months in Hb≤11g/dL patients and 205 months for Hb>11g/dL patients. However, pretreatment anemia according to WHO criteria, and Hb≤11 g/dL in male patients were found to be independent adverse prognostic factors.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Wei KR, Zheng RS, Zhang SW, Liang ZH, Li ZM, Chen WQ.Nasopharyngeal carcinoma incidence and mortality in China, 2013. Chin J Cancer 2017;36:90.
II. Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 2003;21(4):631–637.
III. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol 2007;25:4066-4074.
IV. Topkan E, Ekici NY, Ozdemir Y, Besen AA, Yildirim BA, Mertsoylu H, et al. Baseline hemoglobin <11.0 g/dL has stronger prognostic value than anemia status in nasopharynx cancers treated with chemoradiotherapy. The International Journal of Biological Markers 2019;34(2):139-147.
V. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999;53:113-117.
VI. Vaupel P, Mayer A, Hockel M. Tumor hypoxia and malignant progression. Methods Enzymol 2004;381:335-354.
VII. Dhanapal R, Saraswathi T, Govind RN. Cancer cachexia. J Oral Maxillofac Pathol 2011;15(3):257-260.
VIII. Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998;46(2):135-46.
IX. Lazzari G, Silvano G. From anemia to erythropoietin resistance in head and neck squamous cell carcinoma treatment: a carousel driven by hypoxia. Onco Targets Ther. 2020;13:841-851.
X. Hu K, Harrison LB. Impact of anemia in patients with head and neck cancer treated with radiation therapy. Curr Treat Options Oncol 2005;6(1):31-45.
XI. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001;91(12):2214-2221.
XII. Kumar P.Impact of anemia in patients with head and neck cancer. Oncologist 2000;5(2):13-18.
XIII. Lee WR, Berkey B, Marcial V, Fu KK, Cooper JS, Vikram B, et al. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys 1998;42:1069-1076.
XIV. Jung C, Muller-Klieser W and Vaupel P. Oxygen transport to tissue – VI. In: H. Bicher and D. Reneau (eds) Tumor blood flow and O2 availability during hemodilution. New York: Plenum Press 1984;281-291.
XV. Chua DT, Sham JS and Choy DT. Prognostic impact of hemoglobin levels on treatment outcome in patients with nasopharyngeal carcinoma treated with sequential chemo- radiotherapy or radiotherapy alone. Cancer 2004;101(2):307-316.
XVI. Li J, Chen S, Peng S, Liu Y, Xing S, He X, et al. Prognostic nomogram for patients with nasopharyngeal carcinoma incorporating hematological biomarkers and clinical characteristics. Int J Biol Sci 2018;14(5):549-556.
XVII. Chen C, Chen S, Le QT, Chen J, Chen Z, Li D, et al. Prognostic model for distant metastasis in locally advanced nasopharyngeal carcinoma after concurrent chemoradiotherapy. Head Neck 2015;37(2):209-214.
XVIII. Mai HQ, Mo HY, Hong MH, Guo X, Deng MQ, Zhang F, et al. Impact of pre-radiotherapy hemoglobin level on local control of nasopharyngeal carcinoma. Ai Zheng 2005;24(6):727-730.
XIX. Zhang LL, Zhou GQ, Li YY, Tang LL, Mao YP, Lin AH, et al. Combined prognostic value of pretreatment anemia and cervical node necrosis in patients with nasopharyngeal carcinoma receiving intensity modulated radiotherapy: A large-scale retrospective study. Cancer Med 2017;6(12):2822-2831.